2nd Quarter - Report

BRIDGEBIO PHARMA, INC. for BRIDGEBIO PHARMA, INC.

Firm
Client
Income
—
Expenses
$500,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Orphan drug policies General issues and provisions related to PBM Reform General issues and provisions related to tariffs H.R.1532 and S.822 - Scientific EXPERT Act

LobbyistCovered position, as disclosed
DAVID ADAMS —
SCOTT HINKLE New Sr. Leg. Assistant and Counsel, Policy Dir. and Counsel, Leg. Dir. and Counsel, Deputy Chief of Staff (CoS)/Leg. Dir./Counsel, CoS and Counsel, DC CoS and Counsel, Sr. Advisor and Counsel for Rep. Juan Vargas; CoS and Counsel for Rep. Raul Ruiz
AMANDA MALAKOFF —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1532 (119th), S. 822 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.